Compass rises on positive late-stage trial data for depression drug

COMPASS Pathways

07/07/2026 12:12

** Shares of drug developer Compass Pathways CMPS.O rise 2.5% to $13.16 premarket
** Co says its depression treatment, COMP360, showed durable benefit after six-months of testing in a late-stage trial 
** CMPS says a rolling marketing application submission is underway and final submission remains on track to be completed in Q4
** Co anticipates launch of the drug in the first half of 2027 subject to FDA approval
** Up to last close, stock up 86.1% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))